FDA clears in vivo blood stem cell editing trial; Abeona's $155M PRV sale
Plus, news about CytomX, Valneva, Lenz and Lotus Pharmaceutical: 🧪 After China, US greenlights first trial of in vivo blood stem cell editing: Ensoma
View ArticleExclusive: Patrick Hsu’s startup Stylus Medicine launches, looks beyond...
Stylus Medicine, an ambitious startup founded by Patrick Hsu, has raised $85 million to develop a suite of technologies that it believes will help solve some of the biggest and most competitive ...
View ArticleRoche could rethink $50B US expansion plan if new policies 'harm' operations
Roche said its $50 billion promise to expand its manufacturing footprint in the US has the potential to be “reassessed” — the same day the Swiss pharma added further details on how it would spend part ...
View ArticleRepublican tax cut bill includes PBM, drug price negotiation changes
The latest version of a massive and wide-ranging tax cut bill includes several pro-pharma reforms related to pharmacy benefit managers and the way the drug price negotiation program deals with orphan...
View ArticleTrump's drug price plan is light on details, may have little impact
The White House's plan to realign US drug prices with similar high-income countries has ignited a wave of questions about how or even if drug companies will come to the table and work with the ...
View ArticlePharma investors brush off Trump’s ‘most favored nation’ plan as stocks rise
President Donald Trump on Monday made a sweeping promise to bring down drug prices and stop pharma companies from taking advantage of the US. Wall Street seems unfazed. As details of Trump’s
View ArticleDutch biotech Azafaros gets $146M for Phase 3 trials in three metabolic...
The last time Dutch biotech Azafaros disclosed a financing round — a €25 million Series A — the world was a few weeks away from Covid-19 lockdowns. Five years and three months later, the ...
View ArticleBayer Q1 earnings: 2,000 jobs cut as it homes in on year-end rehaul target
Bayer has been ramping up layoffs in recent months as it edges closer to its end-of-year target to complete its management reorganization that was first announced in 2023. The German conglomerate ...
View ArticleGalapagos backpedals on separation plans, CEO Paul Stoffels exits early
A month ago, former AbbVie and Neumora executive Henry Gosebruch was named the CEO of Galapagos' planned spinout, which would be handed €2.45 billion to hunt for drug candidates and build a ...
View ArticleEndpoints Livestream: Trump's 'most favored nation' plan to cut drug prices
Today on Post Hoc Live, Drew Armstrong is joined by Nick Shipley, the former top lobbyist for the biotech industry, to break down President Trump's "most favored nation" executive order on drug...
View ArticleTIGIT graveyard expands as GSK drops late-stage asset with iTeos
At last year's ESMO conference, there was hope that the TIGIT field still had a leg to stand on as GSK and its partner iTeos propped up their Phase 2 lung cancer ...
View ArticleUnitedHealth Group CEO Andrew Witty steps down
Andrew Witty is out as CEO of UnitedHealth Group after a tumultuous couple of years that included the shooting death of a top executive and a massive cyberattack. Witty, who the company said is...
View ArticleAxsome's $570M loan with Blackstone; Altimmune makes its own credit deal
Plus, news about Neumora, Erasca, FibroGen, Tilt Biotherapeutics, Sangamo, Leap Therapeutics, Remedy Plan, Lexeo, Karyopharm, Tango Therapeutics and Humacyte: Axsome Therapeutics gets Blackstone’s...
View ArticleCytokinetics gets an 'incremental' win for delayed heart drug
Cytokinetics’s aficamten is better than the standard of care in a heart muscle disease, the company said Tuesday. The development is positive, but with aficamten’s approval submission delayed, it will...
View ArticleArcturus to prioritize mRNA therapeutics in bid to boost rare disease programs
Arcturus Therapeutics is doubling down on mRNA technology. The biotech said Monday that it's prioritizing its experimental self-amplifying mRNA drugs, with a focus on programs for cystic fibrosis and a...
View ArticleSome generics, biosimilar drugmakers say they can withstand tariff impact
A handful of generic and biosimilar manufacturers have said they feel prepared to ride out President Donald Trump’s potential pharma-specific tariffs due to their domestic production footprints and not...
View ArticleHHS issues guidance for third round of drug price negotiations
The Trump administration laid out for the first time how Part B drugs could be selected for Medicare drug price negotiations under guidance that seeks to align with and improve transparency in the...
View ArticleCRISPR patent spat revived by federal appeals court ruling
An order from a federal appeals court has kicked the battle wide open again over who holds the key patents for CRISPR-Cas9, a revolutionary gene editing technology. The US Court of Appeals for the...
View ArticleOmada Health joins the digital health IPO corral
On Friday afternoon, Ngai, Shelby and I dropped what we were doing when we saw Omada Health had filed to go public. Omada, the virtual chronic care provider, joins virtual ...
View ArticleAdvocacy groups and experts call for decade-long ban on germline editing
Cell and gene therapy advocacy organizations are jointly calling for a 10-year international moratorium on gene editing of the human germline. They say such use of gene editing comes with questionable...
View ArticleNovo turns to Septerna for oral obesity medicines in deal worth up to $2.2B
Novo Nordisk continues to sling obesity drug partnerships. Its latest biotech of choice is Septerna, which will help the Danish pharma make oral small molecules. Novo will give over $200 million in...
View ArticleGSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope
GSK will hand over $1.2 billion in upfront cash to license a closely-watched candidate for fatty liver disease from Boston Pharmaceuticals. The drug in question is Boston Pharma’s lead asset,...
View ArticleAbbVie doubles down on siRNA with $335M upfront bet on ADARx
After getting into siRNA work with its $1.4 billion acquisition of Aliada Therapeutics late last year, AbbVie is beefing up its presence in the hot subfield of genetic medicines. On Wednesday, AbbVie ...
View Article